Poly Medicure Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Poly Medicure heeft een totaal eigen vermogen van ₹25.9B en een totale schuld van ₹1.6B, wat de schuld-eigenvermogensverhouding op 6.1% brengt. De totale activa en totale passiva bedragen respectievelijk ₹30.5B en ₹4.6B. De EBIT Poly Medicure is ₹3.4B waardoor de rentedekking 376 is. Het heeft contanten en kortetermijnbeleggingen van ₹12.5B.

Belangrijke informatie

6.1%

Verhouding schuld/eigen vermogen

₹1.58b

Schuld

Rente dekkingsratio	376x
Contant	₹12.51b
Aandelen	₹25.91b
Totaal verplichtingen	₹4.61b
Totaal activa	₹30.52b

Recente financiële gezondheidsupdates

Recent updates

Poly Medicure's (NSE:POLYMED) Returns On Capital Not Reflecting Well On The Business

Jan 28

Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

Dec 28

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case

Dec 10

Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Nov 02

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 20

Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

Sep 14

After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Sep 06

Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Aug 14

Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Jul 27

Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Jul 11

Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

May 25

Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

May 12

Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Mar 23

Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Feb 15

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Jan 16

Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Nov 14

Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward

Oct 24

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 22

Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Sep 08

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Aug 12

Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Jul 13

Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Jun 16

Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

Mar 02

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Feb 14

Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

Oct 16

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Sep 28

Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50

Sep 08

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Jun 25

A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)

Jun 07

Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends

May 23

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Feb 23

There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital

Feb 04

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Jan 12

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Oct 14

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₹19.2B ) POLYMED } overtreffen de korte termijn passiva ( ₹4.2B ).

Langlopende schulden: De kortetermijnactiva POLYMED ( ₹19.2B ) overtreffen de langetermijnschulden ( ₹440.1M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: POLYMED heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van POLYMED is de afgelopen 5 jaar gedaald van 35.6% naar 6.1%.

Schuldendekking: De schuld van POLYMED wordt goed gedekt door de operationele kasstroom ( 160.3% ).

Rentedekking: De rentebetalingen op de schuld van POLYMED worden goed gedekt door EBIT ( 376 x dekking).

Balans

Ontdek gezonde bedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/01/31 09:21
Aandelenkoers aan het einde van de dag	2025/01/31 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2024/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Poly Medicure Limited wordt gevolgd door 11 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Nitin Bhasin	Ambit Capital
Karan Khanna	Ambit Capital
Sunita Vaidyanathan	Brics Securities Limited

Poly Medicure Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Recent updates

Poly Medicure's (NSE:POLYMED) Returns On Capital Not Reflecting Well On The Business

Poly Medicure Limited to Report Q3, 2025 Results on Feb 03, 2025

Poly Medicure Limited Appoints Vishal Gupta as Independent Director

Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case

New minor risk - Share price stability

Price target increased by 12% to ₹2,475

Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Poly Medicure Limited to Report Q2, 2025 Results on Oct 28, 2024

Poly Medicure Limited to Report Q2, 2025 Results on Oct 28, 2024

Price target increased by 8.3% to ₹2,198

Poly Medicure Limited Appoints Vimal Bhandari as Non-Executive and Independent Director

Poly Medicure Limited Announces Board Cassation

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

Dividend of ₹3.00 announced

After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Poly Medicure Limited, Annual General Meeting, Sep 26, 2024

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 16%

Poly Medicure Limited has filed a Follow-on Equity Offering in the amount of INR 10 billion.

Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Poly Medicure Limited to Report Q1, 2025 Results on Jul 22, 2024

Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Price target increased by 12% to ₹1,950

Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

Full year 2024 earnings: EPS exceeds analyst expectations

Poly Medicure Limited Recommends Dividend for the Financial Year 2023-24

Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

Poly Medicure Limited to Report Q4, 2024 Results on May 17, 2024

Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Price target increased by 9.4% to ₹1,718

Price target increased by 7.5% to ₹1,620

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Poly Medicure Limited to Report Q3, 2024 Results on Jan 31, 2024

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Poly Medicure Limited to Report Q2, 2024 Results on Nov 04, 2023

Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Upcoming dividend of ₹3.00 per share at 0.2% yield

Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Poly Medicure Limited, Annual General Meeting, Sep 28, 2023

Insufficient new directors

Joint MD & Executive Director recently sold ₹146m worth of stock

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Price target increased by 18% to ₹1,299

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 18%

Poly Medicure Limited to Report Q1, 2024 Results on Aug 07, 2023

Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Investor sentiment improves as stock rises 16%

Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Full year 2023 earnings: EPS exceeds analyst expectations

Poly Medicure Limited Proposes Dividend for the Financial Year 2022-23

Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Third quarter 2023 earnings released: EPS: ₹5.21 (vs ₹3.60 in 3Q 2022)

Poly Medicure Limited to Report Q3, 2023 Results on Jan 28, 2023

Price target increased to ₹1,021

Price target increased to ₹1,021

Second quarter 2023 earnings released: EPS: ₹4.53 (vs ₹3.99 in 2Q 2022)

Poly Medicure Limited to Report Q2, 2023 Results on Nov 04, 2022

Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

Investor sentiment improved over the past week